GlassScriptPhysician profile
Stephanie E Fitzgerald
NPI 1922112226
$1,178.37
in general payments reported to CMS, 2019-2025
10 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $119 · 2021: $116 · 2023: $267 · 2024: $63.23 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $240.10 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $235.63 | 2019-2023 | Cequa |
| Coopervision INC. | $121.80 | 2023-2024 | Misight Contact Lens, Myday Contact Lens |
| Harrow Eye, LLC | $114.89 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $109.23 | 2025 | Xdemvy |
| Alcon Vision LLC | $107.16 | 2019 | |
| Allergan, INC. | $101.96 | 2020 | |
| Bausch & Lomb Americas INC. | $86.46 | 2023 | Infuse |
| Johnson & Johnson Vision Care, INC. | $43.94 | 2025 | |
| Carl Zeiss Meditec Ag | $17.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Fitzgerald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.